Key Highlights

  • Revenue reached USD 12.7 million, up 22% from USD 10.5 million, marking a second straight record quarter.
  • Clinical Solutions jumped 86% to USD 3.2 million, while Lab Essentials rose 9% to USD 9.0 million.
  • Gross Margin widened to 38.0% from 30.7%, and the net loss narrowed to USD 3.5 million, or USD 0.06 a share.
  • An October 2026 offering of 9,200,000 shares at USD 5.00 raised USD 46.0 million gross.

Clinical Solutions Expansion Drives a Second Record Quarter

Alpha Teknova (NASDAQ:TKNO) reported third-quarter 2026 results on November 4, 2026. Based in Hollister, California, the company manufactures life science reagents, including agar plates, culture media and buffers used in drug discovery, Vaccine work and molecular diagnostics. Total Revenue came in at USD 12.7 million. Clinical Solutions revenue climbed to USD 3.2 million from USD 1.7 million, while Lab Essentials grew from USD 8.3 million to USD 9.0 million and other sales contributed USD 0.5 million. Nine-month Clinical Solutions revenue reached USD 7.7 million against USD 4.9 million. The chief executive suggested that custom orders from small and mid-sized biotech clients could hint at better biotech funding, a belief rather than a measured trend. Lab Essentials remains the larger Business by revenue, so the faster Clinical Solutions growth is only beginning to change the mix.

Margin Gains Meet Heavier Sales Spending

Gross profit rose to USD 4.8 million, a 38.0% margin, as higher Volume spread fixed production costs more thinly. Operating expenses increased to USD 8.0 million from USD 7.2 million, reflecting sales headcount and slightly higher administrative outlays, partly cushioned by lower stock compensation. Cash used in operations was USD 1.3 million, and free cash outflow reached USD 1.4 million against USD 2.4 million. Nine-month revenue advanced to USD 36.0 million from USD 30.5 million, and Gross Profit reached USD 13.5 million against USD 10.2 million. A conference call on November 4, 2026 covered results and outlook, and the company introduced its Fill-Tek Dispensing System during the period. Net loss per share narrowed to USD 0.06 from USD 0.08, and Adjusted EBITDA improved by USD 0.6 million on a calculated basis.

Offering Proceeds, Raised Outlook and Share Count

Cash and short-term investments stood at USD 16.6 million at quarter end, against USD 13.2 million of borrowings, before the October raise. Issuing 9,200,000 shares brought in cash but expanded the share base, which dilutes per-share results. Full-year 2026 revenue is now seen at USD 46 million to USD 48 million, up from the prior outlook, while the free cash outflow target stays below USD 8 million. Management plans to attend investor conferences on November 17 and 18, 2026. Because the company still loses money, future financing needs remain a risk. Selling and Marketing expense rose to USD 2.3 million from USD 1.7 million, and general and administrative expense was USD 4.8 million. Because the company still targets a cash outflow for 2026, the raised revenue range must convert into lower burn for the offering to look productive.

Where Things Stand

Growth looks real, but keeping it going depends on biotech Demand and on funding a business that still burns cash. The company raised revenue guidance and reduced its loss, and the October offering adds room beyond the USD 16.6 million on hand at quarter end. The cost is a larger share count. Watch the November investor events, fourth-quarter revenue against the raised range and progress toward the free cash outflow target. The extract does not show how the October proceeds will be split between Debt repayment and operations, so that allocation remains an open question.